Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
Last trade$36.60
Day change-$0.55 (-1.48%)
Day range$36.33 – $37.33
Volume467,277
Market cap$2.74B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.74B
Price / earnings
30.06×
Price / book
6.61×
Price / sales
2.04×
EV / sales
1.96×
EV / EBITDA
19.78×
Profitability
Earnings per share
$1.24
Return on assets
13.47%
Return on equity
21.98%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.93×
Quick ratio
1.93×
Cash ratio
0.49×
Cash flow
Price / cash flow
13.21×
Price / free cash flow
15.23×
Free cash flow
$179.64M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PGNY, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$341.25M
$350.51M
$328.5M
$318.4M
$313.35M
$332.87M
$324.04M
$298.43M
Cost of revenue
$257.51M
$261.21M
$245.43M
$241.52M
$240.51M
$253.9M
$248.24M
$235M
Gross profit
$83.74M
$89.3M
$83.07M
$76.88M
$72.84M
$78.97M
$75.8M
$63.43M
Selling, general and administrative
$48.56M
$49.3M
$47.69M
$61.66M
$51.31M
$54.62M
$51.63M
$47.65M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$48.56M
$49.3M
$47.69M
$61.66M
$51.31M
$54.62M
$51.63M
$47.65M
Operating income
$35.18M
$40M
$35.38M
$15.22M
$21.53M
$24.36M
$24.17M
$15.79M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$36.42M
$41.14M
$36.88M
$17.85M
$23.96M
$27.08M
$26.54M
$17.66M
Income taxes
$10.16M
$13.09M
$12.65M
$5.37M
$10.1M
$9.97M
$11.48M
$7.13M
Net income
$26.25M
$28.05M
$24.23M
$12.49M
$13.86M
$17.11M
$15.06M
$10.53M
Net income attributable to common shareholders
$26.25M
$28.05M
$24.23M
$12.49M
$13.86M
$17.11M
$15.06M
$10.53M
EBITDA
$37.33M
$41.63M
$36.86M
$16.59M
$22.8M
$25.56M
$25.28M
$16.66M
Basic earnings per share
$0.34
$0.36
$0.30
$0.15
$0.16
$0.20
$0.18
$0.12
Diluted earnings per share
$0.32
$0.34
$0.29
$0.14
$0.15
$0.19
$0.17
$0.12
Recent news
Company coverage with links to the original publishers.
Progyny (PGNY), a fertility and family building benefits provider, has earned a Momentum Style Score of A and a Zacks Rank #2 (Buy) rating. The stock has outperformed its industry significantly, gaining 3.85% weekly, 34.7% monthly, and 47.37% annually, compared to the S&P 500's 13.41% yearly return. Recent earnings estimate revisions have also been positive, with upward revisions for both current and next fiscal year estimates.
Progyny reported record results for its 2026 selling season, adding 1.3 million covered lives across 85+ new clients, bringing total coverage to 8.3 million for 2027. The company benefits from competitor exits and restructuring, strengthening its market position. Management raised full-year guidance and has repurchased over 14 million shares since November 2025, demonstrating strong cash generation and shareholder returns.
Progyny (PGNY) shares surged 6.3% following positive insights from its annual selling season, with the company expecting to add 1.2 million new covered lives through the first half of 2027. The fertility benefits provider is projected to report quarterly earnings of $0.51 per share (+13.3% YoY) and revenues of $339.72 million (+8.4% YoY). However, unchanged earnings estimate revisions over the past 30 days suggest the recent rally may lack sustained momentum.
A comparison of two Medical Services stocks reveals that Progyny (PGNY) presents a more attractive value investment opportunity than Charles River Laboratories (CRL). PGNY has a Zacks Rank of #2 (Buy) versus CRL's #3 (Hold), along with superior valuation metrics including a lower forward P/E ratio (12.40 vs 26.89) and a better Value grade (B vs D).
A comparison of two Medical Services sector stocks, Progyny (PGNY) and Charles River Laboratories (CRL), both with Zacks Rank #2 (Buy). Based on valuation metrics including forward P/E ratio (12.92 vs 24.87), PEG ratio (1.12 vs 2.76), and Value grades (B vs D), Progyny is identified as the superior value opportunity.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.